N@N

Alexion Pharmaceuticals (ALXN) Gains As Much As 13.16% After BUYINS.NET Report Predicted On August 30th The Stock Would Rally O

^{Published on 2010-09-28 16:08:25, Last Modified on 2010-12-22 18:47:46 - WOPRAI}
 

September 28, 2010 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on August 30th, 2010 stating that ALXN Alexion Pharmaceuticals (NASDAQ: ALXN) was expected to be higher due to seasonal strength in the stock. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?id=122281

The results of the prediction are the following:

Symbol 8/30/2010 Hi Since $Change % High 9/28/2010 $Change % Today

ALXN $57.52 $65.09 $7.57 13.16% $64.68 $7.16 12.45%

By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. It focuses on products for severe and life-threatening disease states, including hematologic, kidney, and neurologic diseases; transplant rejection; cancer; and autoimmune disorders. The company markets Soliris (eculizumab) for the treatment of patients with paroxysmal nocturnal hemoglobinuria, a blood disorder. It also conducts various Phase II clinical trials on Soliris for the treatment of atypical hemolytic uremic syndrome, MPGN II dense deposit disease, presensitized renal transplant, myasthenia gravis, neuromyelitis optica, multifocal motor neuropathy, and dry age-related macular degeneration. In addition, the company conducts preclinical studies on Soliris for the treatment of presensitized cardiac transplant, cold agglutinin disease, and catastrophic antiphospholipid syndrome. Further, its clinical programs include Samalizumab, which is in Phase I/II clinical trials for the treatment of chronic lymphocytic leukemia and multiple myeloma. Alexion Pharmaceuticals serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company was founded in 1992 and is headquartered in Cheshire, Connecticut.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net